03.

Investors

Here you will find financial calendar, reports, information about the share and corporate governance

Rights Issue

Preliminary time table

1 December 2020 - Last trading  day in NextCell's shares, including the right to receive subscription rights

2 December 2020 - First trading  day in NextCell's shares excluding the right to receive subscription rights

3 December 2020 - Record date  for obtaining subscription rights

3 December 2020 - Beräknad dag för  offentliggörande av prospekt avseende Företrädesemissionen

7 December – 21 December  2020 - Subscription  period for the Rights Issue

7 December – 17 December  2020 - Subscription  rights trading on the Nasdaq First North Growth Market

7 December – around  week 1, 2021 - Trade with paid  subscription “BTA”Around 23  December 2020 - Estimated date  for publication of the outcome of the Rights Issue

Here you will find the prospectus and subscription notes for the Rights Issue

Financial calendar

Q1 report, 2021
29 January, 2021
Q2 report, 2021
29 April, 2021
Q3 report, 2021
30 July, 2021
Year End Report 2021
29 October, 2021
Annual General Meeting
November 24, 2021

Financial reports

2020

2019

2018

2017

2016

2015

Corporate Governance

Certified Adviser

FNCA Sweden AB

Address: Humlegårdsgatan 5, Box 5807, SE-102 48 Stockholm

Phone: +46(0)8-528 00 399

Mail: info@fnca.se

The Share

Shareholders

List of 10 largest shareholders as per November 30, 2020:

‍‍

Owner
Shares
Percentage
Diamyd Medical AB
2,998,703
12.82
Anders Essen-Möller
2,284,534
9.76
Avanza Pension
1,782,733
7.62
Ålandsbanken
770,819
3.29
Pabros AB
593,217
2.54
Nordnet Pensionsförsäkring
577,506
2.47
Christer Jansson
507,258
2.17
Bio All**
467,931
2.00
Konstruktions och försäljningsaktiebolaget
439,765
1,88
Robert Joki
438,888
1.88
Total
10,861,354
46.43
* In addition to Chairman of the Board, Anders Essen-Möller's directly registered holdings, this item includes holdings of 4.98 percent managed by Avanza Pension.

** BioAll AB is controlled by CEO Mathias Svahn and his relatives. This item also includes Mathias Svahn's directly registered holdings of 0.29 percent and holdings managed through Nordnet Pensionsförsäkring of 0.11 percent.

Trading information

NextCell Pharma AB is listed on the Nasdaq First North Growth Market since July 2020. The stock is traded under the ticker “NXTCL”. ISIN Code: SE0009723125.

The current share price is available on Nasdaq First North website:

Nasdaq OMX Nordic

Dividend policy

NextCell has to date paid no dividends to its shareholders. The company is in a development phase, and any surplus is primarily planned for reinvestment in the company’s development.

Archived documents